Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) dropped 6% on Friday . The company traded as low as $4.01 and last traded at $5.02, with a volume of 141,453 shares. The stock had previously closed at $5.34.

CATB has been the subject of a number of research analyst reports. Cowen and Company reiterated a “buy” rating on shares of Catabasis Pharmaceuticls in a report on Wednesday, June 8th. Wedbush reiterated an “outperform” rating and issued a $17.00 target price (down from $27.00) on shares of Catabasis Pharmaceuticls in a report on Tuesday, June 7th. Zacks Investment Research upgraded Catabasis Pharmaceuticls from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a report on Tuesday, July 5th. Finally, Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $28.00 target price on shares of Catabasis Pharmaceuticls in a report on Wednesday, May 25th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $19.05.

The company’s 50 day moving average is $3.99 and its 200-day moving average is $4.96. The stock’s market capitalization is $77.64 million.

Catabasis Pharmaceuticls (NASDAQ:CATB) last issued its earnings results on Thursday, August 11th. The company reported ($0.61) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.04. Analysts expect that Catabasis Pharmaceuticls Inc. will post ($2.50) EPS for the current year.

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.